Literature DB >> 24599999

Novel permissive cell lines for complete propagation of hepatitis C virus.

Mai Shiokawa1, Takasuke Fukuhara, Chikako Ono, Satomi Yamamoto, Toru Okamoto, Noriyuki Watanabe, Takaji Wakita, Yoshiharu Matsuura.   

Abstract

UNLABELLED: Hepatitis C virus (HCV) is a major etiologic agent of chronic liver diseases. Although the HCV life cycle has been clarified by studying laboratory strains of HCV derived from the genotype 2a JFH-1 strain (cell culture-adapted HCV [HCVcc]), the mechanisms of particle formation have not been elucidated. Recently, we showed that exogenous expression of a liver-specific microRNA, miR-122, in nonhepatic cell lines facilitates efficient replication but not particle production of HCVcc, suggesting that liver-specific host factors are required for infectious particle formation. In this study, we screened human cancer cell lines for expression of the liver-specific α-fetoprotein by using a cDNA array database and identified liver-derived JHH-4 cells and stomach-derived FU97 cells, which express liver-specific host factors comparable to Huh7 cells. These cell lines permit not only replication of HCV RNA but also particle formation upon infection with HCVcc, suggesting that hepatic differentiation participates in the expression of liver-specific host factors required for HCV propagation. HCV inhibitors targeting host and viral factors exhibited different antiviral efficacies between Huh7 and FU97 cells. Furthermore, FU97 cells exhibited higher susceptibility for propagation of HCVcc derived from the JFH-2 strain than Huh7 cells. These results suggest that hepatic differentiation participates in the expression of liver-specific host factors required for complete propagation of HCV. IMPORTANCE: Previous studies have shown that liver-specific host factors are required for efficient replication of HCV RNA and formation of infectious particles. In this study, we screened human cancer cell lines for expression of the liver-specific α-fetoprotein by using a cDNA array database and identified novel permissive cell lines for complete propagation of HCVcc without any artificial manipulation. In particular, gastric cancer-derived FU97 cells exhibited a much higher susceptibility to HCVcc/JFH-2 infection than observed in Huh7 cells, suggesting that FU97 cells would be useful for further investigation of the HCV life cycle, as well as the development of therapeutic agents for chronic hepatitis C.

Entities:  

Mesh:

Year:  2014        PMID: 24599999      PMCID: PMC4019116          DOI: 10.1128/JVI.03839-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  90 in total

Review 1.  Animal models for the study of hepatitis C virus infection and related liver disease.

Authors:  Jens Bukh
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

Review 2.  The role of resistance in HCV treatment.

Authors:  Johannes Vermehren; Christoph Sarrazin
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-08       Impact factor: 3.043

3.  Expression of the alpha-fetoprotein gene in pluripotent and committed cells.

Authors:  D S Latchman; H Brzeski; R Lovell-Badge; M J Evans
Journal:  Biochim Biophys Acta       Date:  1984-11-22

4.  Production of infectious hepatitis C virus by using RNA polymerase I-mediated transcription.

Authors:  Takahiro Masaki; Ryosuke Suzuki; Mohsan Saeed; Ken-ichi Mori; Mami Matsuda; Hideki Aizaki; Koji Ishii; Noboru Maki; Tatsuo Miyamura; Yoshiharu Matsuura; Takaji Wakita; Tetsuro Suzuki
Journal:  J Virol       Date:  2010-03-17       Impact factor: 5.103

5.  Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells.

Authors:  Daniel Da Costa; Marine Turek; Daniel J Felmlee; Erika Girardi; Sébastien Pfeffer; Gang Long; Ralf Bartenschlager; Mirjam B Zeisel; Thomas F Baumert
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

6.  Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

Authors:  Holger Hinrichsen; Yves Benhamou; Heiner Wedemeyer; Markus Reiser; Roel E Sentjens; José L Calleja; Xavier Forns; Andreas Erhardt; Jens Crönlein; Ricardo L Chaves; Chan-Loi Yong; Gerhard Nehmiz; Gerhard G Steinmann
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras.

Authors:  Thomas Pietschmann; Artur Kaul; George Koutsoudakis; Anna Shavinskaya; Stephanie Kallis; Eike Steinmann; Karim Abid; Francesco Negro; Marlene Dreux; Francois-Loic Cosset; Ralf Bartenschlager
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

8.  Ontology-based meta-analysis of global collections of high-throughput public data.

Authors:  Ilya Kupershmidt; Qiaojuan Jane Su; Anoop Grewal; Suman Sundaresh; Inbal Halperin; James Flynn; Mamatha Shekar; Helen Wang; Jenny Park; Wenwu Cui; Gregory D Wall; Robert Wisotzkey; Satnam Alag; Saeid Akhtari; Mostafa Ronaghi
Journal:  PLoS One       Date:  2010-09-29       Impact factor: 3.240

9.  Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture.

Authors:  Kyung-Soo Chang; Jieyun Jiang; Zhaohui Cai; Guangxiang Luo
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

10.  Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells.

Authors:  MinKyung Yi; Rodrigo A Villanueva; David L Thomas; Takaji Wakita; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-06       Impact factor: 11.205

View more
  10 in total

1.  Entirely plasmid-based reverse genetics system for rotaviruses.

Authors:  Yuta Kanai; Satoshi Komoto; Takahiro Kawagishi; Ryotaro Nouda; Naoko Nagasawa; Misa Onishi; Yoshiharu Matsuura; Koki Taniguchi; Takeshi Kobayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

2.  Human Cathelicidin Compensates for the Role of Apolipoproteins in Hepatitis C Virus Infectious Particle Formation.

Authors:  Francesc Puig-Basagoiti; Takasuke Fukuhara; Tomokazu Tamura; Chikako Ono; Kentaro Uemura; Yukako Kawachi; Satomi Yamamoto; Hiroyuki Mori; Takeshi Kurihara; Toru Okamoto; Hideki Aizaki; Yoshiharu Matsuura
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

3.  Completion of the Entire Hepatitis C Virus Life Cycle in Vero Cells Derived from Monkey Kidney.

Authors:  Asako Murayama; Nao Sugiyama; Takaji Wakita; Takanobu Kato
Journal:  mBio       Date:  2016-06-14       Impact factor: 7.867

4.  Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C.

Authors:  Esperance A K Schaefer; James Meixiong; Christina Mark; Amy Deik; Daniel L Motola; Dahlene Fusco; Andrew Yang; Cynthia Brisac; Shadi Salloum; Wenyu Lin; Clary B Clish; Lee F Peng; Raymond T Chung
Journal:  World J Gastroenterol       Date:  2016-12-07       Impact factor: 5.742

Review 5.  Engineered Livers for Infectious Diseases.

Authors:  Nil Gural; Liliana Mancio-Silva; Jiang He; Sangeeta N Bhatia
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2017-11-22

6.  Characterization of miR-122-independent propagation of HCV.

Authors:  Chikako Ono; Takasuke Fukuhara; Daisuke Motooka; Shota Nakamura; Daisuke Okuzaki; Satomi Yamamoto; Tomokazu Tamura; Hiroyuki Mori; Asuka Sato; Kentaro Uemura; Yuzy Fauzyah; Takeshi Kurihara; Takahiro Suda; Akira Nishio; Su Su Hmwe; Toru Okamoto; Tomohide Tatsumi; Tetsuo Takehara; Kazuaki Chayama; Takaji Wakita; Kazuhiko Koike; Yoshiharu Matsuura
Journal:  PLoS Pathog       Date:  2017-05-11       Impact factor: 6.823

7.  Quasispecies of Hepatitis C Virus Participate in Cell-Specific Infectivity.

Authors:  Takasuke Fukuhara; Satomi Yamamoto; Chikako Ono; Shota Nakamura; Daisuke Motooka; Hiroyuki Mori; Takeshi Kurihara; Asuka Sato; Tomokazu Tamura; Takashi Motomura; Toru Okamoto; Michio Imamura; Toru Ikegami; Tomoharu Yoshizumi; Yuji Soejima; Yoshihiko Maehara; Kazuaki Chayama; Yoshiharu Matsuura
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

8.  The irreversible HCV-associated risk of gastric cancer following interferon-based therapy: a joint study of hospital-based cases and nationwide population-based cohorts.

Authors:  Chun-Wei Chen; Jur-Shan Cheng; Tai-Di Chen; Puo-Hsien Le; Hsin-Ping Ku; Ming-Ling Chang
Journal:  Therap Adv Gastroenterol       Date:  2019-06-17       Impact factor: 4.409

9.  A robust model of natural hepatitis C infection using hepatocyte-like cells derived from human induced pluripotent stem cells as a long-term host.

Authors:  Khanit Sa-Ngiamsuntorn; Adisak Wongkajornsilp; Phetcharat Phanthong; Suparerk Borwornpinyo; Narisorn Kitiyanant; Wasun Chantratita; Suradej Hongeng
Journal:  Virol J       Date:  2016-04-05       Impact factor: 4.099

10.  Development of hepatoma-derived, bidirectional oval-like cells as a model to study host interactions with hepatitis C virus during differentiation.

Authors:  Masahiko Ito; Suofeng Sun; Takasuke Fukuhara; Ryosuke Suzuki; Miho Tamai; Toyohiko Yamauchi; Kenji Nakashima; Yoh-Ichi Tagawa; Shigetoshi Okazaki; Yoshiharu Matsuura; Takaji Wakita; Tetsuro Suzuki
Journal:  Oncotarget       Date:  2017-07-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.